問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
洪逸平
下載
2021-12-27 - 2026-01-17
Condition/Disease
Test Drug
Participate Sites7Sites
Not yet recruiting3Sites
Recruiting4Sites
2021-04-30 - 2025-04-30
Participate Sites1Sites
Recruiting1Sites
2021-04-01 - 2024-03-15
Participate Sites2Sites
Recruiting2Sites
2019-11-01 - 2025-02-28
Advanced Hepatocellular Carcinoma (HCC)
Camrelizumab (SHR-1210)、Rivoceranib (Apatinib) mesylate
Participate Sites8Sites
Recruiting8Sites
2019-08-01 - 2024-10-30
HBV
YIV-906
Recruiting7Sites
2024-09-02 - 2027-12-31
Participate Sites3Sites
Recruiting3Sites
2021-05-03 - 2022-07-07
2022-01-03 - 2023-12-31
Participate Sites4Sites
2022-01-30 - 2025-06-30
2021-11-01 - 2027-03-20
全部
